The European Commission’s decision to issue a marketing authorization came after the European Medicine Agency’s Committee for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

Regeneron Pharmaceuticals ( NASDAQ: REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting ...

Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.

New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal ...

D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.